Projektrelevante Publikationen

Brown GD et al. Hidden Killers: human fungal infections. Sci Transl Med 2012; 4: 165rv13.

Lanternier F et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54: 1629-1636.

Lanternier F et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54: S35-43.

Roden MM et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.

Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-13.

Skiada A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-1867.

Hibbett DS et al. A higher-level phylogenetic classification of the fungi. Mycol Res 2007; 111: 509-547.

Sun HY et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009; 9: 2166-2171.

Spellberg B et al. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005; 18: 556-569.

Ribes JA et al. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.

Auberger J et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with haematological malignancies. Int J Haematol 2008; 88: 508-515.

Auberger J et al. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-center institutional retrospective observational study. J Antimicrob Chemother 2012; 67: 2268-2273.

Kontoyiannis DP et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.

Trifilio SM et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-429.

Rüping MJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.

Petrikkos G et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54: S23-34.

Perkhofer S et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 2010; 36: 531-536.

Lass-Flörl C et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-104.

Lass-Flörl C et al. Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. J Clin Microbiol 2013; 51: 863-868.

Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 2009; 15: 60-65.

Tramsen L et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy 2013; 15: 344-351.

Schmidt S et al. Characterization of the cellular immune responses to Rhizopus orzae with potential  impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis 2012; 206: 135-139.

Schmidt S et al. Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity. Immunobiology 2013; 218: 939-944.

Roilides E et al. Host defences against zygomycetes. Clin Infect Dis 2012; 54: S61-66.

Ibrahim AS and Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis 2013; 26: 508-515.

Kontoyiannis DP et al. Future directions in mucormycosis research. Clin Infect Dis 2012; 54: S79-85.

Ibrahim AS et al. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54: 16-22.

Blum G et al. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clin Microbiol Infect 2008; 14: 1146-1151.

Weber DJ et al. The role of the surface environment in healthcare-associated infections. Curr Opin Infect Dis 2013; 26: 338-344.

Lass-Flörl et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131:201-207.

Weber DJ et al. Understanding and preventing transmission of healthcare-associated pathogens due to the contaminated hospital environment. Infect Control Hosp Epidemiol 2013; 34: 449-452.

Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin N Am 2011; 25: 201-225.

Cardo D et al. Moving toward elimination of healthcare-associated infections: a call to action. Infect Control Hosp Epidemiol 2010; 31: 1101-1105.

Weber DJ et al. Self-disinfecting surfaces: review of current methodologies and future prospects. Am J Infect Control 2013; 41: S31-35.

Salgado CD et al. Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit. Infect Control Hosp Epidemiol 2013; 34: 479-486.

Lorenz K et al. Anodic TiO2 nanotube layers electrochemically filled with MoO3 and their antimicrobial properties. Biointerphases 2011; 6: 16-21.

Zollfrank C et al. Antimicrobial activity of transition metal acid MoO3 prevents microbial growth on material surfaces. Mat Sci Eng C Mater Biol Appl 2012; 32: 47-54.

Fallon J et al. Galleria mellonella as a model for fungal pathogenicity testing. Methods Mol Biol 2012; 845: 469-485.

Speth C et al. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility. Med Microbiol Immunol 2013; 202: 379-389.

Kim JH et al. Targeting the oxidative stress response system of fungi with redox-potent chemosensitizing agents. Front Microbiol. 2012; 3: 88.

Kim JH et al. Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and Cryptococcus with natural dihydroxybenzaldehydes. Front Microbiol 2012; 3: 261.

Shirazi F et al. Mitochondrial respiratory pathways inhibition in Rhizopus oryzae potentiates activity of posaconazole and itraconazole via apoptosis. PLoS One 2013; 8: e63393.

Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. Clin Microbiol Infect 2008; 14: 982-984.

Li DM et al. Rhino-orbital-cerebral mycosis and cavernous thrombosis. Eur J Inflamm 2014; 12: 1-10

Speth C et al. Platelets as immune cells in infectious diseases. Future Microbiol 2013; 8: 1431-1451.

Speth C et al. Complement and fungal pathogens: an update. Mycoses 2008; 51: 477-496.

Cuenca-Estrella M et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18: 9-18.

Cornely OA et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20: 5-26.

Tortorano AM et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 2014; 20: 27-46.

Arendrup MC et al. Breakpoints for antifungal agents: an update from EUCAST focusing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013; 16: 81-95.

Lackner M et al. Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol 2014; 9: 683-695.

Li X et al. Selection of optimal oligonucleotide probes for microarrays using multiple criteria, global alignment and parameter estimation. Nucleic Acids Res 2005; 33: 6114-6123.

Xiang MJ et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 2013; 13: 386-393.

Alexander BD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-1732.

Fischer J et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 2014; 69: 1533-1536.

Chowdhary A et al. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 2014; 69: 555-557.

Cleary JD et al. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52: 2263-2265.

Douglas CM et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471-2479.

Balashov SV et al. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-2063.

Bader O et al. Cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013; 57: 3513-3517.

Warnes SL and Keevil CW. Inactivation of norovirus on dry copper alloy surfaces. PLOSone 2013; 8: e75017.

Garey KW et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.

Chamilos G et al. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.

Christian Doppler Labor für invasive Pilzinfektionen


CD Labor für invasive Pilzinfektionen
Schöpfstr. 41/2. Stock
A-6020 Innsbruck

Tel:  +43 (0)512 9003-70703

Tel:  +43 (0)512 9003-70721

Fax: +43 (0)512 9003-73700



CD Labor für invasive Pilzinfektionen
Schöpfstr. 41/2. Stock
A-6020 Innsbruck

Tel:  +43 (0)512 9003-70703

Tel:  +43 (0)512 9003-70721

Fax: +43 (0)512 9003-73700